[
    {
        "id": 5936,
        "drug_name": "Epcoritamab",
        "clinical_trial_id": "NCT04628494",
        "has_trial_insight_page": 1,
        "indication": "B-cell Lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ABBV\/news\/137657",
        "note": "Approved May 19, 2023.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5936,
        "drug_name": "Epcoritamab",
        "clinical_trial_id": "NCT04628494",
        "has_trial_insight_page": 1,
        "indication": "B-cell Lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ABBV\/news\/137657",
        "note": "Approved May 19, 2023.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9896,
        "drug_name": "AYVAKIT (avapritinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Non-advanced systemic mastocytosis (SM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BPMC\/news\/137966",
        "note": "FDA approval on May 22, 2023.",
        "company_entity_id": 439,
        "company_ticker": "BPMC",
        "company_name": "Blueprint Medicines Corporation",
        "company_price": "89.7000",
        "company_change": 0.23,
        "company_percent_change": 0.26,
        "company_optionable": 1,
        "company_number_of_shares": 61232297,
        "price_change_sparkline": [
            [
                79.53,
                1706677200
            ],
            [
                79.88,
                1706763600
            ],
            [
                79.58,
                1706850000
            ],
            [
                76.66,
                1707109200
            ],
            [
                77.17,
                1707195600
            ],
            [
                74.2,
                1707282000
            ],
            [
                74.16,
                1707368400
            ],
            [
                76.54,
                1707454800
            ],
            [
                77.54,
                1707714000
            ],
            [
                73.17,
                1707800400
            ],
            [
                76.8,
                1707886800
            ],
            [
                87.57,
                1707973200
            ],
            [
                90.26,
                1708059600
            ],
            [
                91.25,
                1708405200
            ],
            [
                87.26,
                1708491600
            ],
            [
                86,
                1708578000
            ],
            [
                89.49,
                1708664400
            ],
            [
                95.05,
                1708923600
            ],
            [
                99.79,
                1709010000
            ],
            [
                95.45,
                1709096400
            ],
            [
                93.52,
                1709182800
            ],
            [
                95.12,
                1709269200
            ],
            [
                90.8,
                1709528400
            ],
            [
                89.67,
                1709614800
            ],
            [
                90.38,
                1709701200
            ],
            [
                92.04,
                1709787600
            ],
            [
                92.3,
                1709874000
            ],
            [
                89.47,
                1710129600
            ],
            [
                89.7,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5607,
        "drug_name": "OPVEE (nalmefene)",
        "clinical_trial_id": "NCT04828005",
        "has_trial_insight_page": 0,
        "indication": "Opioid Overdose",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-23",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/INVVY\/news\/138021",
        "note": "Approved May 22, 2023.",
        "company_entity_id": 587,
        "company_ticker": "OPNT",
        "company_name": "Opiant Pharmaceuticals Inc.",
        "company_price": "20.6500",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 10335628,
        "statuses": []
    },
    {
        "id": 5607,
        "drug_name": "OPVEE (nalmefene)",
        "clinical_trial_id": "NCT04828005",
        "has_trial_insight_page": 0,
        "indication": "Opioid Overdose",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-23",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/INVVY\/news\/138021",
        "note": "Approved May 22, 2023.",
        "company_entity_id": 2250,
        "company_ticker": "INDV",
        "company_name": "Indivior PLC",
        "company_price": "21.1600",
        "company_change": -0.99,
        "company_percent_change": -4.47,
        "company_optionable": 1,
        "company_number_of_shares": 136237077,
        "price_change_sparkline": [
            [
                17.64,
                1706677200
            ],
            [
                17.36,
                1706763600
            ],
            [
                17.51,
                1706850000
            ],
            [
                17.4,
                1707109200
            ],
            [
                18.28,
                1707195600
            ],
            [
                17.39,
                1707282000
            ],
            [
                17.79,
                1707368400
            ],
            [
                17.73,
                1707454800
            ],
            [
                17.85,
                1707714000
            ],
            [
                17.51,
                1707800400
            ],
            [
                17.85,
                1707886800
            ],
            [
                18.09,
                1707973200
            ],
            [
                17.56,
                1708059600
            ],
            [
                16.66,
                1708405200
            ],
            [
                17.5,
                1708491600
            ],
            [
                21.3,
                1708578000
            ],
            [
                21.28,
                1708664400
            ],
            [
                21.4,
                1708923600
            ],
            [
                22.25,
                1709010000
            ],
            [
                21.9,
                1709096400
            ],
            [
                21.43,
                1709182800
            ],
            [
                23,
                1709269200
            ],
            [
                22.09,
                1709528400
            ],
            [
                21.69,
                1709614800
            ],
            [
                21.28,
                1709701200
            ],
            [
                22.05,
                1709787600
            ],
            [
                21.3,
                1709874000
            ],
            [
                22.15,
                1710129600
            ],
            [
                21.16,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5132,
        "drug_name": "XACDURO (sulbactam for injection; durlobactam for injection)",
        "clinical_trial_id": "NCT03894046",
        "has_trial_insight_page": 0,
        "indication": "Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/INVA\/news\/138253",
        "note": "Approved May 24, 2023.",
        "company_entity_id": 391,
        "company_ticker": "INVA",
        "company_name": "Innoviva Inc.",
        "company_price": "14.8200",
        "company_change": 0.03,
        "company_percent_change": 0.2,
        "company_optionable": 1,
        "company_number_of_shares": 63227333,
        "price_change_sparkline": [
            [
                16.2,
                1706677200
            ],
            [
                16.29,
                1706763600
            ],
            [
                15.9,
                1706850000
            ],
            [
                15.82,
                1707109200
            ],
            [
                15.89,
                1707195600
            ],
            [
                15.53,
                1707282000
            ],
            [
                15.6,
                1707368400
            ],
            [
                15.69,
                1707454800
            ],
            [
                15.71,
                1707714000
            ],
            [
                15.48,
                1707800400
            ],
            [
                15.8,
                1707886800
            ],
            [
                16,
                1707973200
            ],
            [
                15.86,
                1708059600
            ],
            [
                15.8,
                1708405200
            ],
            [
                15.67,
                1708491600
            ],
            [
                15.48,
                1708578000
            ],
            [
                15.48,
                1708664400
            ],
            [
                15.52,
                1708923600
            ],
            [
                15.37,
                1709010000
            ],
            [
                15.35,
                1709096400
            ],
            [
                15.28,
                1709182800
            ],
            [
                15.24,
                1709269200
            ],
            [
                15.26,
                1709528400
            ],
            [
                14.88,
                1709614800
            ],
            [
                15.18,
                1709701200
            ],
            [
                15.08,
                1709787600
            ],
            [
                14.84,
                1709874000
            ],
            [
                14.79,
                1710129600
            ],
            [
                14.82,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5132,
        "drug_name": "XACDURO (sulbactam for injection; durlobactam for injection)",
        "clinical_trial_id": "NCT03894046",
        "has_trial_insight_page": 0,
        "indication": "Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/INVA\/news\/138253",
        "note": "Approved May 24, 2023.",
        "company_entity_id": 484,
        "company_ticker": "ZLAB",
        "company_name": "Zai Lab Limited",
        "company_price": "19.5400",
        "company_change": -0.47,
        "company_percent_change": -2.35,
        "company_optionable": 1,
        "company_number_of_shares": 99208743,
        "price_change_sparkline": [
            [
                21.57,
                1706677200
            ],
            [
                22.51,
                1706763600
            ],
            [
                22.5,
                1706850000
            ],
            [
                22.12,
                1707109200
            ],
            [
                21.61,
                1707195600
            ],
            [
                19.66,
                1707282000
            ],
            [
                19.605,
                1707368400
            ],
            [
                18.68,
                1707454800
            ],
            [
                18.21,
                1707714000
            ],
            [
                17.73,
                1707800400
            ],
            [
                19.39,
                1707886800
            ],
            [
                19.89,
                1707973200
            ],
            [
                20.64,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                19.91,
                1708491600
            ],
            [
                20.08,
                1708578000
            ],
            [
                19.94,
                1708664400
            ],
            [
                20.99,
                1708923600
            ],
            [
                22.49,
                1709010000
            ],
            [
                20.8,
                1709096400
            ],
            [
                20.98,
                1709182800
            ],
            [
                21.1,
                1709269200
            ],
            [
                20.42,
                1709528400
            ],
            [
                18.91,
                1709614800
            ],
            [
                19.8,
                1709701200
            ],
            [
                19.16,
                1709787600
            ],
            [
                18.91,
                1709874000
            ],
            [
                20.01,
                1710129600
            ],
            [
                19.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7632,
        "drug_name": "PAXLOVID (ritonavir) - (EPIC-HR)",
        "clinical_trial_id": "NCT05047601",
        "has_trial_insight_page": 1,
        "indication": "Oral Protease Inhibitor for COVID-19",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-25",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/138663",
        "note": "FDA approved on May 25, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7233,
        "drug_name": "INPEFA (sotagliflozin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Heart failure",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-05-26",
        "link": "https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-fda-approves-lexicon-pharmas-heart-failure-drug-2023-05-26\/",
        "note": "Approved May 26, 2023.",
        "company_entity_id": 190,
        "company_ticker": "LXRX",
        "company_name": "Lexicon Pharmaceuticals Inc.",
        "company_price": "2.5200",
        "company_change": -0.29000000000000004,
        "company_percent_change": -10.32,
        "company_optionable": 1,
        "company_number_of_shares": 244924695,
        "price_change_sparkline": [
            [
                1.87,
                1706677200
            ],
            [
                1.98,
                1706763600
            ],
            [
                2.13,
                1706850000
            ],
            [
                2.05,
                1707109200
            ],
            [
                2.21,
                1707195600
            ],
            [
                2.15,
                1707282000
            ],
            [
                2.3,
                1707368400
            ],
            [
                2.39,
                1707454800
            ],
            [
                2.92,
                1707714000
            ],
            [
                2.93,
                1707800400
            ],
            [
                3.32,
                1707886800
            ],
            [
                3.58,
                1707973200
            ],
            [
                3.18,
                1708059600
            ],
            [
                2.65,
                1708405200
            ],
            [
                2.51,
                1708491600
            ],
            [
                2.37,
                1708578000
            ],
            [
                2.54,
                1708664400
            ],
            [
                2.44,
                1708923600
            ],
            [
                2.62,
                1709010000
            ],
            [
                2.61,
                1709096400
            ],
            [
                2.49,
                1709182800
            ],
            [
                2.48,
                1709269200
            ],
            [
                2.21,
                1709528400
            ],
            [
                2.25,
                1709614800
            ],
            [
                2.19,
                1709701200
            ],
            [
                2.15,
                1709787600
            ],
            [
                2.17,
                1709874000
            ],
            [
                2.81,
                1710129600
            ],
            [
                2.52,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6418,
        "drug_name": "LYNPARZA (olaparib) - (PROpel)",
        "clinical_trial_id": "NCT03732820",
        "has_trial_insight_page": 1,
        "indication": "Castration-resistant prostate cancer -first line",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/139619",
        "note": "FDA Approved on June 1, 2023.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6418,
        "drug_name": "LYNPARZA (olaparib) - (PROpel)",
        "clinical_trial_id": "NCT03732820",
        "has_trial_insight_page": 1,
        "indication": "Castration-resistant prostate cancer -first line",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/139619",
        "note": "FDA Approved on June 1, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8020,
        "drug_name": "ABRYSVO (RSVpreF)",
        "clinical_trial_id": "NCT05035212",
        "has_trial_insight_page": 1,
        "indication": "Respiratory syncytial virus (RSV) vaccine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/139535",
        "note": "Approved June 1, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Breakthrough Therapy Designation (BTD)",
                "abbreviation": "BTD",
                "description": "Breakthrough Therapy Designation (BTD)",
                "description_html": "<p>Breakthrough Therapy Designation (BTD)<\/p>\n"
            }
        ]
    },
    {
        "id": 10188,
        "drug_name": "PREVYMIS (Letermovir)",
        "clinical_trial_id": "NCT03443869",
        "has_trial_insight_page": 0,
        "indication": "Prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (D+\/R-)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-05",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRK\/news\/140378",
        "note": "Approved on June 5, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9754,
        "drug_name": "LINZESS (linaclotide)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Functional Constipation in pediatric patients aged 6-17",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-12",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/IRWD\/news\/141307",
        "note": "FDA Approved on June 12, 2023.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9754,
        "drug_name": "LINZESS (linaclotide)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Functional Constipation in pediatric patients aged 6-17",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-12",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/IRWD\/news\/141307",
        "note": "FDA Approved on June 12, 2023.",
        "company_entity_id": 175,
        "company_ticker": "IRWD",
        "company_name": "Ironwood Pharmaceuticals Inc.",
        "company_price": "8.6900",
        "company_change": -0.26,
        "company_percent_change": -2.91,
        "company_optionable": 1,
        "company_number_of_shares": 156528648,
        "price_change_sparkline": [
            [
                14.19,
                1706677200
            ],
            [
                14.6,
                1706763600
            ],
            [
                14.59,
                1706850000
            ],
            [
                14.75,
                1707109200
            ],
            [
                14.87,
                1707195600
            ],
            [
                14.87,
                1707282000
            ],
            [
                14.9,
                1707368400
            ],
            [
                15.32,
                1707454800
            ],
            [
                15.37,
                1707714000
            ],
            [
                15.2,
                1707800400
            ],
            [
                15.45,
                1707886800
            ],
            [
                14.99,
                1707973200
            ],
            [
                14.58,
                1708059600
            ],
            [
                14.83,
                1708405200
            ],
            [
                15.14,
                1708491600
            ],
            [
                14.86,
                1708578000
            ],
            [
                15.07,
                1708664400
            ],
            [
                15.03,
                1708923600
            ],
            [
                15.18,
                1709010000
            ],
            [
                15.12,
                1709096400
            ],
            [
                9.43,
                1709182800
            ],
            [
                9.065,
                1709269200
            ],
            [
                9.33,
                1709528400
            ],
            [
                9.32,
                1709614800
            ],
            [
                8.62,
                1709701200
            ],
            [
                8.93,
                1709787600
            ],
            [
                9.01,
                1709874000
            ],
            [
                8.95,
                1710129600
            ],
            [
                8.69,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6461,
        "drug_name": "BYLVAY (odevixibat)",
        "clinical_trial_id": "NCT04674761",
        "has_trial_insight_page": 1,
        "indication": "Alagille syndrome (ALGS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-13",
        "link": "https:\/\/www.ipsen.com\/press-releases\/u-s-fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome\/",
        "note": "FDA Approved on June 13, 2023.",
        "company_entity_id": 2251,
        "company_ticker": "IPSEY",
        "company_name": "Ipsen ADR",
        "company_price": "29.1600",
        "company_change": 0.03,
        "company_percent_change": 0.1,
        "company_optionable": 0,
        "company_number_of_shares": 328117684,
        "price_change_sparkline": [
            [
                29.095,
                1706677200
            ],
            [
                28.85,
                1706763600
            ],
            [
                28.85,
                1706850000
            ],
            [
                28,
                1707109200
            ],
            [
                28.28,
                1707195600
            ],
            [
                29.2,
                1707282000
            ],
            [
                28.495,
                1707368400
            ],
            [
                28.664,
                1707454800
            ],
            [
                28.664,
                1707714000
            ],
            [
                28.22,
                1707800400
            ],
            [
                27.82,
                1707886800
            ],
            [
                28.5,
                1707973200
            ],
            [
                28.405,
                1708059600
            ],
            [
                28.874,
                1708405200
            ],
            [
                28.0425,
                1708491600
            ],
            [
                28.295,
                1708578000
            ],
            [
                28.4675,
                1708664400
            ],
            [
                28.06,
                1708923600
            ],
            [
                28.185,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.86,
                1709182800
            ],
            [
                27.74,
                1709269200
            ],
            [
                27.78,
                1709528400
            ],
            [
                27.498,
                1709614800
            ],
            [
                27.69,
                1709701200
            ],
            [
                28.69,
                1709787600
            ],
            [
                28.31,
                1709874000
            ],
            [
                29.13,
                1710129600
            ],
            [
                29.16,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10439,
        "drug_name": "PEMRYDI RTU (Injectable)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Metastatic non-squamous non-small cell lung cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-14",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AMRX\/news\/141623",
        "note": "FDA 505(b)(2) Approval on June 14, 2023.",
        "company_entity_id": 543,
        "company_ticker": "AMRX",
        "company_name": "Amneal Pharmaceuticals Inc.",
        "company_price": "5.3100",
        "company_change": -0.06999999999999995,
        "company_percent_change": -1.3,
        "company_optionable": 1,
        "company_number_of_shares": 306544199,
        "price_change_sparkline": [
            [
                5.35,
                1706677200
            ],
            [
                5.51,
                1706763600
            ],
            [
                5.52,
                1706850000
            ],
            [
                5.52,
                1707109200
            ],
            [
                5.6,
                1707195600
            ],
            [
                5.36,
                1707282000
            ],
            [
                5.46,
                1707368400
            ],
            [
                5.57,
                1707454800
            ],
            [
                5.85,
                1707714000
            ],
            [
                5.6,
                1707800400
            ],
            [
                5.82,
                1707886800
            ],
            [
                5.89,
                1707973200
            ],
            [
                5.9,
                1708059600
            ],
            [
                5.78,
                1708405200
            ],
            [
                5.73,
                1708491600
            ],
            [
                5.69,
                1708578000
            ],
            [
                5.8,
                1708664400
            ],
            [
                5.82,
                1708923600
            ],
            [
                5.71,
                1709010000
            ],
            [
                5.52,
                1709096400
            ],
            [
                5.52,
                1709182800
            ],
            [
                5.47,
                1709269200
            ],
            [
                5.4,
                1709528400
            ],
            [
                5.34,
                1709614800
            ],
            [
                5.31,
                1709701200
            ],
            [
                5.31,
                1709787600
            ],
            [
                5.39,
                1709874000
            ],
            [
                5.38,
                1710129600
            ],
            [
                5.31,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8691,
        "drug_name": "Columvi (glofitamab-gxbm)",
        "clinical_trial_id": "NCT03075696",
        "has_trial_insight_page": 0,
        "indication": "B-Cell Non-Hodgkin's Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-16",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RHHBY\/news\/142060",
        "note": "FDA Approved on June 16, 2023.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5062,
        "drug_name": "CAMZYOS  (Mavacamten) - (VALOR-HCM)",
        "clinical_trial_id": "NCT04349072",
        "has_trial_insight_page": 1,
        "indication": "Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-16",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BMY\/news\/142065",
        "note": "FDA Approval on June 16, 2023",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5062,
        "drug_name": "CAMZYOS  (Mavacamten) - (VALOR-HCM)",
        "clinical_trial_id": "NCT04349072",
        "has_trial_insight_page": 1,
        "indication": "Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-16",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BMY\/news\/142065",
        "note": "FDA Approval on June 16, 2023",
        "company_entity_id": 1022,
        "company_ticker": "LIAN",
        "company_name": "LianBio",
        "company_price": "4.9500",
        "company_change": 0.03,
        "company_percent_change": 0.61,
        "company_optionable": 0,
        "company_number_of_shares": 108062638,
        "price_change_sparkline": [
            [
                4.11,
                1706677200
            ],
            [
                4.18,
                1706763600
            ],
            [
                4.13,
                1706850000
            ],
            [
                4.12,
                1707109200
            ],
            [
                4.17,
                1707195600
            ],
            [
                4.1,
                1707282000
            ],
            [
                4.09,
                1707368400
            ],
            [
                4.14,
                1707454800
            ],
            [
                4.04,
                1707714000
            ],
            [
                4.8,
                1707800400
            ],
            [
                4.76,
                1707886800
            ],
            [
                4.78,
                1707973200
            ],
            [
                4.77,
                1708059600
            ],
            [
                4.79,
                1708405200
            ],
            [
                4.79,
                1708491600
            ],
            [
                4.79,
                1708578000
            ],
            [
                4.79,
                1708664400
            ],
            [
                4.81,
                1708923600
            ],
            [
                4.815,
                1709010000
            ],
            [
                4.82,
                1709096400
            ],
            [
                4.84,
                1709182800
            ],
            [
                4.88,
                1709269200
            ],
            [
                4.89,
                1709528400
            ],
            [
                4.92,
                1709614800
            ],
            [
                4.94,
                1709701200
            ],
            [
                4.9,
                1709787600
            ],
            [
                4.93,
                1709874000
            ],
            [
                4.92,
                1710129600
            ],
            [
                4.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8027,
        "drug_name": "VYVGART Hytrulo (efgartigimod)",
        "clinical_trial_id": "NCT04735432",
        "has_trial_insight_page": 1,
        "indication": "Generalized Myasthenia Gravis (gMG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ARGX\/news\/142687",
        "note": "FDA Approved on June 20, 2023.",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8027,
        "drug_name": "VYVGART Hytrulo (efgartigimod)",
        "clinical_trial_id": "NCT04735432",
        "has_trial_insight_page": 1,
        "indication": "Generalized Myasthenia Gravis (gMG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ARGX\/news\/142687",
        "note": "FDA Approved on June 20, 2023.",
        "company_entity_id": 415,
        "company_ticker": "ARGX",
        "company_name": "argenx SE",
        "company_price": "387.9400",
        "company_change": 2.94,
        "company_percent_change": 0.76,
        "company_optionable": 1,
        "company_number_of_shares": 55395856,
        "price_change_sparkline": [
            [
                380.51,
                1706677200
            ],
            [
                385.58,
                1706763600
            ],
            [
                378.84,
                1706850000
            ],
            [
                403.37,
                1707109200
            ],
            [
                393.12,
                1707195600
            ],
            [
                391.95,
                1707282000
            ],
            [
                394.89,
                1707368400
            ],
            [
                401.48,
                1707454800
            ],
            [
                392.7,
                1707714000
            ],
            [
                386.83,
                1707800400
            ],
            [
                390.27,
                1707886800
            ],
            [
                393.47,
                1707973200
            ],
            [
                392.23,
                1708059600
            ],
            [
                395.4,
                1708405200
            ],
            [
                399.95,
                1708491600
            ],
            [
                406.01,
                1708578000
            ],
            [
                409.52,
                1708664400
            ],
            [
                410.35,
                1708923600
            ],
            [
                411.2,
                1709010000
            ],
            [
                397.7,
                1709096400
            ],
            [
                380.01,
                1709182800
            ],
            [
                393.49,
                1709269200
            ],
            [
                390.32,
                1709528400
            ],
            [
                388.69,
                1709614800
            ],
            [
                390.66,
                1709701200
            ],
            [
                388.68,
                1709787600
            ],
            [
                387.8,
                1709874000
            ],
            [
                385,
                1710129600
            ],
            [
                387.94,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8027,
        "drug_name": "VYVGART Hytrulo (efgartigimod)",
        "clinical_trial_id": "NCT04735432",
        "has_trial_insight_page": 1,
        "indication": "Generalized Myasthenia Gravis (gMG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ARGX\/news\/142687",
        "note": "FDA Approved on June 20, 2023.",
        "company_entity_id": 484,
        "company_ticker": "ZLAB",
        "company_name": "Zai Lab Limited",
        "company_price": "19.5400",
        "company_change": -0.47,
        "company_percent_change": -2.35,
        "company_optionable": 1,
        "company_number_of_shares": 99208743,
        "price_change_sparkline": [
            [
                21.57,
                1706677200
            ],
            [
                22.51,
                1706763600
            ],
            [
                22.5,
                1706850000
            ],
            [
                22.12,
                1707109200
            ],
            [
                21.61,
                1707195600
            ],
            [
                19.66,
                1707282000
            ],
            [
                19.605,
                1707368400
            ],
            [
                18.68,
                1707454800
            ],
            [
                18.21,
                1707714000
            ],
            [
                17.73,
                1707800400
            ],
            [
                19.39,
                1707886800
            ],
            [
                19.89,
                1707973200
            ],
            [
                20.64,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                19.91,
                1708491600
            ],
            [
                20.08,
                1708578000
            ],
            [
                19.94,
                1708664400
            ],
            [
                20.99,
                1708923600
            ],
            [
                22.49,
                1709010000
            ],
            [
                20.8,
                1709096400
            ],
            [
                20.98,
                1709182800
            ],
            [
                21.1,
                1709269200
            ],
            [
                20.42,
                1709528400
            ],
            [
                18.91,
                1709614800
            ],
            [
                19.8,
                1709701200
            ],
            [
                19.16,
                1709787600
            ],
            [
                18.91,
                1709874000
            ],
            [
                20.01,
                1710129600
            ],
            [
                19.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7923,
        "drug_name": "TALZENNA (talazoparib) and XTANDI (enzalutamide) - (TALAPRO-2)",
        "clinical_trial_id": "NCT04821622",
        "has_trial_insight_page": 1,
        "indication": "Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-06-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/142690",
        "note": "FDA Approved on June 20, 2023",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    }
]